Welcome to our dedicated page for AVROBIO news (Ticker: AVRO), a resource for investors and traders seeking the latest updates and insights on AVROBIO stock.
This page contains historical news coverage for AVROBIO, Inc. (AVRO), which operated as a clinical-stage biotechnology company developing lentiviral gene therapies for rare genetic diseases. The company merged with Tectonic Therapeutic and no longer operates independently. This news archive provides context on AVROBIO's development programs, clinical progress, and the strategic decisions that led to its merger.
AVROBIO's news flow historically centered on clinical trial updates, particularly data from its gene therapy programs targeting lysosomal storage disorders. Announcements regarding patient enrollment, interim data readouts, and safety monitoring formed the core of the company's investor communications. Manufacturing developments and regulatory interactions also generated coverage, as gene therapy requires specialized production capabilities and evolving regulatory frameworks.
Strategic news became prominent as the company navigated capital allocation decisions and evaluated its development portfolio. Asset sales, partnership discussions, and ultimately the exploration of strategic alternatives reflected the resource-intensive nature of gene therapy development. The merger announcement with Tectonic Therapeutic marked the culmination of this strategic review process, redirecting shareholder value toward different therapeutic programs.
This historical archive allows investors and researchers to trace AVROBIO's evolution from a focused gene therapy developer through its clinical milestones and eventual corporate transformation. The news timeline documents both the scientific progress and business realities of developing complex therapies for rare disease populations.
AVROBIO, Inc. reported 2022 financial results, showing a net loss of $105.9 million for the year, improving from $119.1 million in 2021. The company plans to initiate a global Phase 2/3 trial for Gaucher disease type 3 in late 2023 after receiving favorable regulatory feedback. Additionally, dosing in a Phase 1/2 trial for cystinosis has completed, with updates expected at the ASGCT annual meeting in May 2023. AVROBIO ended 2022 with $92.6 million in cash, sufficient to fund operations into Q1 2024. Research and development expenses decreased to $72.2 million for the year, compared to $83.1 million in 2021.
AVROBIO, a clinical-stage gene therapy company, will have its senior management participate in the 'Orphan Neuro Corporate Panel' at Cowen’s 43rd Annual Health Care Conference on March 7, 2023, at 10:30 AM ET in Boston. This event highlights AVROBIO's commitment to addressing genetic diseases through innovative gene therapies. The panel will be webcast live and archived for 90 days on avrobio.com. AVROBIO is focused on developing treatments for conditions such as Gaucher disease and cystinosis using its proprietary plato® platform, aimed at durable therapeutic benefits.
AVROBIO (Nasdaq: AVRO) announced the presentation of updated data at the 19th Annual WORLD Symposium in Orlando, Florida, from February 22-26, 2023. The reports include promising results showing complete biochemical correction in the first pediatric Gaucher disease type 3 patient treated with hematopoietic stem cell gene therapy. Furthermore, data from a fully enrolled Phase 1/2 clinical trial in cystinosis will also be shared. Key presentations on gene therapy for mucopolysaccharidosis type II and ongoing clinical trials for Gaucher and cystinosis will be highlighted, emphasizing AVROBIO's commitment to advancing gene therapy solutions.
AVROBIO, Inc. (Nasdaq: AVRO) announced the granting of 7,500 restricted stock units (RSUs) to a new employee as an inducement award under its 2019 Inducement Plan. The RSUs were granted on
AVROBIO has released new interim data on its investigational gene therapy AVR-RD-02 for Gaucher disease, showcasing positive outcomes from both pediatric GD3 and adult GD1 patients. A pediatric patient demonstrated complete biochemical correction and significant health improvements 15 months post-treatment. Additionally, the first four adult patients in a GD1 trial showed important reductions in liver and spleen volume up to two years post-therapy. Following favorable discussions with regulatory bodies, a global registrational Phase 2/3 clinical trial for GD3 is set for late 2023.
AVROBIO, Inc. (NASDAQ: AVRO) announced a virtual update on its Gaucher Disease Program for analysts and investors scheduled for December 7, 2022, at 8 am ET. The update will cover advancements in its clinical program focused on Gaucher disease, including new pharmacodynamic and efficacy data extending to two years post-gene therapy. The company will also discuss a prospective Phase 2/3 clinical trial and its overall development strategy. Guests will include experts in lysosomal disorders and pediatric stem cell transplants.
AVROBIO, a gene therapy company, reported its third quarter financial results for 2022, highlighting a decrease in net loss to $23 million from $32.6 million in 2021. Research and development expenses fell to $15.9 million, driven by reduced program development costs. The company also received rare pediatric disease designations for its investigational therapies for Gaucher disease and cystinosis. A comprehensive update on the Gaucher disease program is scheduled for December 7, 2022. As of September 30, 2022, AVROBIO had $116 million in cash, expected to support operations into Q1 2024.
AVROBIO (NASDAQ: AVRO) announced participation in a virtual panel on 'Genomic Medicines – Evolving Regulatory Environment and Path to Approval' at the Sixth Annual Barclays Gene Editing/Therapy Summit.
The event is scheduled for Monday, Nov. 14, 2022, at 12:30 PM ET. AVROBIO focuses on gene therapy for genetic diseases, including cystinosis and Gaucher disease, utilizing its proprietary plato® platform to enhance clinical development.
AVROBIO, a clinical-stage gene therapy company, announced the granting of 13,000 restricted stock units (RSUs) to two new employees under its 2019 Inducement Plan. These RSUs were awarded on November 1, 2022, to encourage the new hires' acceptance of employment. The RSUs will vest over four years, with the initial 25% vesting after one year and the remainder vesting annually thereafter. This initiative aligns with Nasdaq Listing Rule 5635(c)(4), reinforcing the company's commitment to talent acquisition.
AVROBIO, Inc. announced that the FDA granted Rare Pediatric Disease Designation to its investigational gene therapy AVR-RD-02 for treating Gaucher disease. This designation aims to facilitate drug development for rare pediatric diseases and offers potential benefits, including a priority review voucher for future applications. AVR-RD-02 targets Gaucher disease type 1 and type 3, affecting approximately 30,000 patients globally. Interim clinical data updates are expected in Q4 2022.
FAQ
What is the current stock price of AVROBIO (AVRO)?
What is the market cap of AVROBIO (AVRO)?
